AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
NEW DELHI, Aug 1 Asia Pulse - Japanese drug maker Daichii Sankyo (TSE: 4568), which has signed a share purchase agreement with Ranbaxy (BSE: 500359), on Thursday said its open offer for an additional 20 per cent stake in the domestic pharma major would undergo a change of schedule, pursuant to a delay in Securities and Exchange Board of India's (SEBI) approval.
In a public announcement, Daiichi Sankyo said it is yet to receive market regulator Sebi's approval for an open offer to pick up a further 20 per cent stake in the domestic pharma major, which was sent to SEBI on June 27.
"Hence the schedule of activities as per the disclosure made in the public announcement will undergo change," Daiichi Sankyo said. The offer was scheduled to open on August 8 and close on August 27.
"The revised schedule of activities in respect of the offer pertaining to acquisition of the equity shares of Ranbaxy Laboratories Ltd will be announced separately after receiving SEBI's ...
Source: HighBeam Research, DAIICHI'S OPEN OFFER FOR 20 PCT STAKE IN RANBAXY AWAITS SEBI'S NOD.